The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: A systematic analysis of the peer-reviewed literature from 1966 to April 2008

Thyroid

Volumn 20, Issue 11, 2010, Pages 1235-1245

  Sacks, Wendy ^a   Fung, Constance H ^b   Chang, John T ^c   Waxman, Alan ^a   Braunstein, Glenn D ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Zynx Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE;

ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DIFFERENTIATED THYROID CANCER; DISEASE FREE SURVIVAL; DISTANT METASTASIS; HIGH RISK PATIENT; HUMAN; MEDLINE; PEER REVIEW; POSTOPERATIVE CARE; PRIORITY JOURNAL; SURVIVAL RATE; SYSTEMATIC REVIEW; THYROID CANCER; TUMOR ABLATION; TUMOR VOLUME;

ADULT; CARCINOMA; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK; THYROID GLAND; THYROID NEOPLASMS;

EID: 78249255814     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2009.0455     Document Type: Article

References (84)

1. Seidlin SM, Marinelli LD, Oshry E 1990 Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. CA Cancer J Clin 40:299-317.
2. Shaha AR 2007 TNM classification of thyroid carcinoma. World J Surg 31:879-887.
3. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1058.
4. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 19:1167-214.
5. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J, Wiersinga W, European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803.
6. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 16:1229-1242.
7. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR 2002 Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 26:879-885.
8. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
9. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504-515.
10. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP 2009 Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 19:451-457.
11. Mazzaferri E 2004 A randomized trial of remnant ablation-in search of an impossible dream? J Clin Endocrinol Metab 89:3662-3664.
12. Lang BH, Lo CY, Chan WF, Lam KY, Wan KY 2007 Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg 245:366-378.
13. Chow SM, Law SC, Mendenhall WM, Au SK, Chan PT, Leung TW, Tong CC, Wong IS, Lau WH 2002 Papillary thyroid carcinoma: prognostic factors and the role of radioiodine and external radiotherapy. Int J Radiat Oncol Biol Phys 52:784-795.
14. Podnos YD, Smith D, Wagman LD, Ellenhorn JD 2005 Radioactive iodine offers survival improvement in patients with follicular carcinoma of the thyroid. Surgery 138:1072-1076.
15. Lal G, O'Dorisio T, McDougall R, Weigel RJ 2008 Cancer of the head and neck. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG (eds). Abeloff's Clinical Oncology. Churchill Livingstone Elsevier, Philadelphia, p 148.
16. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673.
17. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzò G, Meringolo D, Ferretti E, Sacco R, Arturi F, Filetti S 2004 Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89:3402-3407.
18. Mazzaferri EL, Kloos RT 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463.
19. Lo CY, Chan WF, Lam KY, Wan KY 2004 Optimizing the treatment of AMES high-risk papillary thyroid carcinoma. World J Surg 28:1103-1109.
20. Cunningham MP, Duda RB, Recant W, Chmiel JS, Sylvester JA, Fremgen A 1990 Survival discriminants for differentiated thyroid cancer. Am J Surg 160:344-347.
21. Mazzaferri EL 1997 Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid 7:265-271.
22. Podnos YD, Smith DD, Wagman LD, Ellenhorn JD 2007 Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol 96:3-7.
23. Sanders LE, Cady B 1998 Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg 133:419-425. (Pubitemid 28193527)
24. Pelizzo MR, Boschin IM, Toniato A, Piotto A, Bernante P, Pagetta C, Rampin L, Rubello D 2006 Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. Eur J Surg Oncol 32:1144-1148.
25. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP 1997 Pathological tumor-node metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 82:3553-3562.
26. De Groot LJ, Kaplan EL, McCormick M, Straus FH 1990 Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414-424.
27. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB 1998 The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 82:375-388.
28. Morris DM, Boyle PJ, Stidley CA, Altobelli KK, Parnell T, Key C 1998 Localized well-differentiated thyroid carcinoma: survival analysis of prognostic factors and (131) I therapy. Ann Surg Oncol 5:329-337.
29. De Groot LJ, Kaplan EL, Shukla MS, Salti G, Straus FH 1995 Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 80:2946-2953.
30. Staunton MD 1994 Thyroid cancer: a multivariate analysis on influence of treatment on long-term survival. Eur J Surg Oncol 20:613-621.
31. Pelizzo MR, Boschin IM, Toniato A, Piotto A, Pagetta C, Gross MD, Al-Nahhas A, Rubello D 2007 Papillary thyroid carcinoma: 35-year outcome and prognostic factors in 1858 patients. Clin Nucl Med 32:440-444.
32. Coburn MC, Wanebo HJ 1992 Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 164:671-676.
33. Brierley J, Tsang R, Panzarella T, Bana N 2005 Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf) 63:418-427.
34. Saadi H, Kleidermacher P, Esselstyn C, Jr. 2001 Conservative management of patients with intrathyroidal welldifferentiated follicular thyroid carcinoma. Surgery 130:30-35.
35. th ed. Springer-Verlag, New York.
36. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR 1998 Outcome after treatment of high-risk papillary and non-Hurthle-cell follicular thyroid carcinoma. Ann Intern Med 129:622-627. (Pubitemid 28480817)
37. Chow SM, Law SC, Mendenhall WM, Au SK, Yau S, Yuen KT, Law CC, Lau WH 2002 Follicular thyroid carcinoma: prognostic factors and the role of radioiodine. Cancer 95:488-498.
38. Kuijpens JL, Hansen B, Hamming JF, Ribot JG, Haak HR, Coebergh JW 1998 Trends in treatment and long-term survival of thyroid cancer in southeastern Netherlands, 1960-1992. Eur J Cancer 34:1235-1241.
39. Jung TS, Kim TY, Kim KW, Oh YL, Park do J, Cho BY, Shong YK, Kim WB, Park YJ, Jung JH, Chung JH 2007 Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. Endocr J 54:265-274.
40. Yildirim E 2005 A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. J Am Coll Surg 200:378-392.
41. Cross S, Wei JP, Kim S, Brams DM 2006 Selective surgery and adjuvant therapy based on risk classifications of welldifferentiated thyroid cancer. J Surg Oncol 94:678-682.
42. Kim S, Wei JP, Braveman JM, Brams DM 2004 Predicting outcome and directing therapy for papillary thyroid carcinoma. Arch Surg 139:390-394.
43. Gemsenjager E, Heitz PU, Seifert B, Martina B, Schweizer I 2001 Differentiated thyroid carcinoma. Follow-up of 264 patients from one institution for up to 25 years. Swiss Med Wkly 131:157-163.
44. Hay ID, McConahey WM, Goellner JR 2002 Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2, 512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 113:241-260.
45. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, Ordonez NG 1992 The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714-720.
46. Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, Shah JP, Shaha AR 2003 Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 197:191-197.
47. Samaan NA, Schultz PN, Haynie TP, Ordonez NG 1985 Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 60:376-380.
48. Balan KK, Raouf AH, Critchley M 1994 Outcome of 249 patients attending a nuclear medicine department with well differentiated thyroid cancer; a 23 year review. Br J Radiol 67:283-291. (Pubitemid 24081546)
49. Zettinig G, Fueger BJ, Passler C, Kaserer K, Pirich C, Dudczak R, Niederle B 2002 Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma-surgery or conventional therapy? Clin Endocrinol (Oxf) 56:377-382.
50. Jarzab B, Handkiewicz JD, Wloch J, Kalemba B, Roskosz J, Kukulska A, Puch Z 2000 Multivariate analysis of prognostic factors for differentiated thyroid carcinoma in children. Eur J Nucl Med 27:833-841.
51. Tseng LM, Lee CH, Wang HC, Shyr YM, Chiu JH, Wu CW, Lui WY, P'eng FK 1996 The surgical treatment and prognostic factors of well-differentiated thyroid cancers in Chinese patients: a 20-year experience. Zhonghua Yi Xue Za Zhi (Taipei) 58:121-131.
52. Varma VM, Beierwaltes WH, Nofal MM, Nishiyama RH, Copp JE 1970 Treatment of thyroid cancer. Death rates after surgery and after surgery followed by sodium iodide I-131. JAMA 214:1437-1442.
53. Mihailovic J, Stefanovic L, Malesevic M 2007 Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors. Cancer Biother Radiopharm 22:250-255.
54. Massin JP, Savoie JC, Garnier H, Guiraudon G, Leger FA, Bacourt F 1984 Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 53:982-992.
55. Wong JB, Kaplan MM, Meyer KB, Pauker SG 1990 Ablative radioactive iodine therapy for apparently localized thyroid carcinoma. A decision analytic perspective. Endocrinol Metab Clin North Am 19:741-760.
56. Zidan J, Kassem S, Kuten A 2000 Follicular carcinoma of the thyroid gland: prognostic factors, treatment, and survival. Am J Clin Oncol 23:1-5.
57. Sanders LE, Silverman M 1998 Follicular and Hurthle cell carcinoma: predicting outcome and directing therapy. Surgery 124:967-974.
58. Segal K, Shpitzer T, Hazan A, Bachar G, Marshak G, Popovtzer A 2006 Invasive well-differentiated thyroid carcinoma: effect of treatment modalities on outcome. Otolaryngol Head Neck Surg 134:819-822.
59. Rosa Pelizzo M, Toniato A, Boschin IM, Piotto A, Bernante P, Pagetta C, Palazzi M, Maria Guolo A, Preo P, Nibale O, Rubello D 2005 Locally advanced differentiated thyroid carcinoma: a 35-year mono-institutional experience in 280 patients. Nucl Med Commun 26:965-968.
60. Coburn M, Teates D, Wanebo HJ 1994 Recurrent thyroid cancer. Role of surgery versus radioactive iodine (I131). Ann Surg 219:587-593.
61. Davis NL, Gordon M, Germann E, McGregor GI, Robins RE 1992 Efficacy of 131I ablation following thyroidectomy in patients with invasive follicular thyroid cancer. Am J Surg 163:472-475.
62. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, Sherman SI 2003 Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 97:1186-1194.
63. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR 3rd 1998 Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8:737-744.
64. Martins RG, Caplan RH, Lambert PJ, Rooney B, Kisken WA 1997 Management of thyroid cancer of follicular cell origin: Gundersen/Lutheran Medical Center. J Am Coll Surg 185:388-397. (Pubitemid 27419197)
65. Herrera MF, López-Graniel CM, Saldaña J, Gamboa-Domínguez A, Richaud-Patín Y, Vargas-Vorackova F, Angeles-Angeles A, Llorente L, Castillo C, Pérez B, Rivera R, González O, Rull J 1996 Papillary thyroid carcinoma in Mexican patients: clinical aspects and prognostic factors. World J Surg 20:94-99.
66. Palme CE, Waseem Z, Raza SN, Eski S, Walfish P, Freeman JL 2004 Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 130:819-824. (Pubitemid 38915967)
67. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, Cailleux AF, Lumbroso JD, Parmentier C, Schlumberger M 1998 Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 83:553-559.
68. Handkiewicz-Junak D, Wloch J, Roskosz J, Krajewska J, Kropinska A, Pomorski L, Kukulska A, Prokurat A, Wygoda Z, Jarzab B 2007 Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 48:879-888.
69. Chow SM, Yau S, Kwan CK, Poon PC, Law SC 2006 Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer 13:1159-1172.
70. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC 2004 Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668-3676.
71. Obaldo JM, Silvestre dela Cruz T, Bidana AFM, Bandong-Reyes E, Cruz RM 1989 Post-surgical iodine-131 therapy in differentiated thyroid cancer. J Intern Med 27:301-308.
72. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S, Goldstein DP 2008 An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. Endocrinol Metab Clin North Am 37:457-480.
73. 2 Thyroid 17:1225-1228.
74. Young RL, Mazzaferri EL, Rahe AJ, Dorfman SG 1980 Pure follicular thyroid carcinoma: impact of therapy in 214 patients. J Nucl Med 21:733-737.
75. Bhattacharyya N, Chien W 2006 Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann Otol Rhinol Laryngol 115:607-610.
76. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J, Wiersinga W 2005 Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 153:651-659.
77. Hughes CJ, Shaha AR, Shah JP, Loree TR 1996 Impact of lymph node metastatsis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 18:127-132.
78. Mazzaferi EL, Jhiang SM 1995 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-28.
79. Shah BR, Laupacis A, Hux JE, Austin PC 2005 Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 58:550-559.
80. Sturmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S 2006 A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol 59:437-447.
81. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R 1998 The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 228:320-330.
82. Grumbach K, Anderson GM, Luft HS, Roos LL, Brook R 1995 Regionalization of cardiac surgery in the United States and Canada. Geographic access, choice, and outcomes. JAMA 274:1282-1288.
83. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH 1996 Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 334:701-707.
84. Hannan EL, Racz M, Ryan TJ, McCallister BD, Johnson LW, Arani DT, Guerci AD, Sosa J, Topol EJ 1997 Coronary angioplasty volume-outcome relationships for hospitals and cardiologists. JAMA 277:892-898.